Follow us...


Search News Archives

News Channels


Coronavirus (COVID-19)


View Channel

New Laboratory Products


View Channel

Lab News


View Channel

Research & Case Studies


View Channel

Microscopy | Image Analysis


View Channel

Separation Science


View Channel



View Channel

Events | Webinars


View Channel

Conferences | Events

Inoviem Scientific Enters into Service-Based Partnership with XoNovo

publication date: Sep 18, 2018
author/source: Inoviem Scientific

inoviemInoviem Scientific, a Contract Research Biotech (CRB), announces a service-based partnership with XoNovo, a preclinical-stage biopharmaceutical company developing a proprietary small molecule for the treatment of neurodegenerative diseases.

Financial terms of the partnership were not disclosed.

The partnership aims to generate crucial information concerning XoNovo’s lead compound, XN001, a patented new chemical entity (NCE); an autophagy modulator for the treatment of neurodegenerative diseases. According to the agreement, Inoviem will apply its expertise and cutting-edge technological solutions to isolate and identify XN001’s therapeutic targets and elucidate its mode of action.

This partnership is in line with Inoviem’s long-term strategy, focused on broadening international connections, lowering risks in drug discovery and development projects, and supporting its partners in bringing promising therapeutics to the clinic with the ultimate goal of improving patients’ lives.

The synergy between the two companies will enable XoNovo to strengthen its pipeline/portfolio by validating XN001’s mode of action.
For Inoviem, this agreement is a service-based partnership. The company plans to continue such collaborations in the future. This ‘win-win’ agreement paves the way for the collaborative strategy that Inoviem Scientific is keen to develop.

“There is uncertainty in all drug development processes. We must think anew. The goal of our collaboration with XoNovo is to provide a therapeutic solution for patients with neurodegenerative diseases,” said Dr. Pierre Eftekhari, founder and president of Inoviem Scientific.

“We are excited to collaborate with Inoviem, and, through this partnership, accelerate our technology with the aim of curing neurodegenerative diseases using the exciting novel mechanism of autophagy enhancement,” said Dr. Ido Nevo, XoNovo’s CEO.



Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:




Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd




Media Partners